Prothena Corporation plc Ordinary Shares (PRTA)
Stock · NASDAQ · Health Care
$8.36as of 10/16/2026
Price chart
Active signals
PRTA Signal Track Record
How signals performed across all stocks →What PRTA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | -1.9% | 41% | September 4, 2026 |
| Bollinger Band Breakdown | 25 | -4.4% | 36% | September 15, 2026 |
| Bollinger Band Breakout | 16 | +1.3% | 50% | August 10, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +2.1% | 56% | September 8, 2026 |
| Any 20-session window (baseline) | -2.6% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PRTA
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an inve…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 67
- Website
- www.prothena.com/
Fundamentals
- 1-day range
- $8.24$8.61
- Market cap
- $449.19M
- P/E (trailing)
- —
- P/E (forward)
- -6.35
- EPS (trailing)
- $-0.83
- Dividend yield
- —
- Beta
- -0.23
- Avg. volume
- 488.5K
How Prothena Corporation plc Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Prothena Corporation plc Ordinary Shares Competitors
Chosen by industry and closest market cap.
- PRTAProthena Corporation plc Ordinary Shares$8.35▼ 1.76%Market cap $449.19MP/E —$7.73$11.8
- BNTCBenitec Biopharma Inc. Common Stock$8.11▼ 4.14%Market cap $451.07MP/E —$8.52$16.76
- RZLTRezolute Inc. Common Stock (NV)$3.58▼ 8.21%Market cap $452.57MP/E —$1.07$11.46
- LRMRLarimar Therapeutics Inc. Common Stock$1.99▼ 0.25%Market cap $436.31MP/E —$2.06$6.42
- ASMBAssembly Biosciences Inc. Common Stock$20.09▼ 2.33%Market cap $420.36MP/E 333.50$19.98$39.71
- EVMNEvommune Inc. Common Stock$5.17▼ 12.82%Market cap $481.93MP/E —$6.52$33.2
- QTTBQ32 Bio Inc. Common Stock$7.52▼ 3.22%Market cap $482.18MP/E 7.95$1.91$23.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PRTA Prothena Corporation plc Ordinary Shares | $449.19M | — | $8.35 | ▼ 1.76% | $7.73$11.8 |
| BNTC Benitec Biopharma Inc. Common Stock | $451.07M | — | $8.11 | ▼ 4.14% | $8.52$16.76 |
| RZLT Rezolute Inc. Common Stock (NV) | $452.57M | — | $3.58 | ▼ 8.21% | $1.07$11.46 |
| LRMR Larimar Therapeutics Inc. Common Stock | $436.31M | — | $1.99 | ▼ 0.25% | $2.06$6.42 |
| ASMB Assembly Biosciences Inc. Common Stock | $420.36M | 333.50 | $20.09 | ▼ 2.33% | $19.98$39.71 |
| EVMN Evommune Inc. Common Stock | $481.93M | — | $5.17 | ▼ 12.82% | $6.52$33.2 |
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 7.95 | $7.52 | ▼ 3.22% | $1.91$23.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?Yahoo · 10/8/2026
- 4 Alzheimer's Drug Stocks to Watch on World Alzheimer's DayYahoo · 9/21/2026
Insider Activity
Insider Actions →- William P. Scully · October 8, 2026 · Buy90.0K @ $8.57
- William P. Scully · October 7, 2026 · Buy125.0K @ $8.4
- William P. Scully · October 2, 2026 · Buy100.0K @ $8.57
- William P. Scully · September 28, 2026 · Buy103.5K @ $8.6
- William P. Scully · September 18, 2026 · Buy100.0K @ $8.43
- William P. Scully · September 2, 2026 · Buy27.0K @ $9.47
- William P. Scully · August 20, 2026 · Buy50.0K @ $8.79
- William P. Scully · August 18, 2026 · Gift627.6K
- William P. Scully · August 17, 2026 · Gift336.0K
- William P. Scully · August 10, 2026 · Gift251.6K
- William P. Scully · August 7, 2026 · Buy3.5K @ $8.62
- William P. Scully · August 7, 2026 · Buy34.0K @ $8.62
- Anne Evans Kingston · July 29, 2026 · Sale7.7K @ $8.47
- Michael John Isaacs · July 29, 2026 · Sale8.4K @ $8.47
- Wagner M. Zago · July 28, 2026 · Option Exercise51.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prothena included in Alzheimer's Day stock watchlist
Prothena was featured in a Yahoo Finance article listing four Alzheimer's drug stocks to watch on World Alzheimer's Day. This inclusion highlights the company's relevance in the neurodegenerative disease sector. The stock is currently trading near its 52-week low, with technical indicators showing a rejection at support levels.
Prothena included in Alzheimer's Day stock watchlist. Prothena was featured in a Yahoo Finance article listing four Alzheimer's drug stocks to watch on World Alzheimer's Day. This inclusion highlights the company's relevance in the neurodegenerative disease sector. The stock is currently trading near its 52-week low, with technical indicators showing a rejection at support levels.